We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

61 hedge funds and large institutions have $64.2M invested in Theriva Biologics in 2016 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 8

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

9% more funds holding

Funds holding: 56 → 61 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

15% less capital invested

Capital invested by funds: $75.5M → $64.2M (-$11.4M)

Holders
61
Holders Change
+5
Holders Change %
+8.93%
% of All Funds
1.63%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
19
Increased
14
Reduced
8
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$3.93M
2
State Street
State Street
Massachusetts
+$1.77M
3
Northern Trust
Northern Trust
Illinois
+$1.52M
4
BIT
BlackRock Institutional Trust
California
+$1.34M
5
BIM
BlackRock Investment Management
Delaware
+$584K

Top Sellers

Rank Fund Capital Flow
1
MP
MSD Partners
New York
-$2.35M
2
William Blair & Company
William Blair & Company
Illinois
-$1.07M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$987K
4
CS
Credit Suisse
Switzerland
-$339K
5
UBS Group
UBS Group
Switzerland
-$320K
Name Holding Trade Value Shares
Change 		Change in
Stake
California Public Employees Retirement System
26
California Public Employees Retirement System
California
$181K – – –
SBIA
27
Sheaff Brock Investment Advisors
Indiana
$156K +$37.6K +2 +25%
LTFS
28
Ladenburg Thalmann Financial Services
Florida
$153K – – –
Cambridge Investment Research Advisors
29
Cambridge Investment Research Advisors
Iowa
$137K – – –
RhumbLine Advisers
30
RhumbLine Advisers
Massachusetts
$126K +$151K +8 New
Manulife (Manufacturers Life Insurance)
31
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$106K +$132K +7 New
VKH
32
Virtu KCG Holdings
New York
$106K +$132K +7 New
Millennium Management
33
Millennium Management
New York
$92K -$151K -8 -57%
NFA
34
Nationwide Fund Advisors
Ohio
$86K +$94.1K +5 New
AIG
35
American International Group
New York
$78.4K +$94.1K +5 New
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$77K +$56.5K +3 +150%
HighTower Advisors
37
HighTower Advisors
Illinois
$76K – – –
VOYA Investment Management
38
VOYA Investment Management
Georgia
$69K +$75.3K +4 New
M&T Bank
39
M&T Bank
New York
$66K – – –
BA
40
BlackRock Advisors
Delaware
$65K +$37.6K +2 +100%
Creative Planning
41
Creative Planning
Kansas
$59K – – –
CS
42
Credit Suisse
Switzerland
$58K -$339K -18 -82%
HLA
43
Hamilton Lane Advisors
Pennsylvania
$52K – – –
Stifel Financial
44
Stifel Financial
Missouri
$47K – – –
Fisher Asset Management
45
Fisher Asset Management
Washington
$46K +$37.6K +2 +200%
SO
46
STRS Ohio
Ohio
$45K +$56.5K +3 New
Jacobs Levy Equity Management
47
Jacobs Levy Equity Management
New Jersey
$44K +$56.5K +3 New
MWM
48
Mission Wealth Management
California
$42K – – –
WS
49
Wedbush Securities
California
$40K – – –
Citadel Advisors
50
Citadel Advisors
Florida
$39K – – –
1
2
3 4

TOVX Hedge Fund Activity: Q2 2016 in Review

61 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2016, worth a combined $64.2M — down 15% from $75.5M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new TOVX positions and 14 closed out — a net gain of 5 holders — while 14 added to existing stakes and 8 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $3.93M. The largest seller was MSD Partners, cutting an estimated $2.35M.

  • 61 institutional investors held Theriva Biologics (TOVX) as of Q2 2016, up from 56 in Q1 2016.
  • Funds reported $64.2M of Theriva Biologics stock for Q2 2016, down 15% quarter-over-quarter.
  • 19 funds opened new Theriva Biologics positions in Q2 2016 and 14 closed out, a net change of +5 holders.
  • The largest Theriva Biologics buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $3.93M added.
  • The largest Theriva Biologics seller in Q2 2016 was MSD Partners, an estimated $2.35M sold.

Based on aggregated 13F filings for Q2 2016.